Erythromycin Ethylsuccinate (erythromycin ethylsuccinate)
Last reviewed · Source: First Databank (FDB) drug data
Overview
Erythromycin ethylsuccinate is a macrolide antibiotic.
USES: Erythromycin is used to treat a wide variety of bacterial infections. It may also be used to prevent certain bacterial infections. Erythromycin is known as a macrolide antibiotic.
It works by stopping the growth of bacteria. This antibiotic treats or prevents only bacterial infections. It will not work for viral infections (such as common cold, flu).
Using any antibiotic when it is not needed can cause it to not work for future infections.
Generic name: erythromycin ethylsuccinate
Pronunciation: (e-RITH-roe-MYE-sin ETH-il-SUX-i-nate)
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Erythromycin Ethylsuccinate
Indications
The following indications are listed for Erythromycin Ethylsuccinate:
- Acute Bacterial Otitis Media
- Acute Bacterial Sinusitis
- Acute Streptococcal Pyogenes Bacterial Sinusitis
- Acute Streptococcus Pneumoniae Bacterial Sinusitis
- Bacterial Pneumonia
- Chlamydia Cervicitis
- Chlamydia Trachomatis Urethritis
- Chlamydial Conjunctivitis
- Chlamydial Pneumonia
- Diphtheria
- Diphtheria Carrier State
- Erythrasma
- Legionnaires' Disease
- Listeriosis
- Mycoplasmal Pneumonia
- Neonatal Pneumonia
- Nongonococcal Urethritis
- Pertussis
- Pharyngitis Due To Streptococcus Pyogenes
- Pneumococcal Acute Otitis Media
- Pneumococcal Pharyngitis
- Pneumococcal Pneumonia
- Post-Exposure Diphtheria Prevention
- Preoperative Bowel Preparation
- Rectal Chlamydia Trachomatis Infection
- Rheumatic Fever Prevention
- Skin And Skin Structure Infection
- Skin And Skin Structure Streptococcus Pyogenes Infection
- Staphylococcus Aureus Skin And Skin Structure Infection
- Streptococcus Acute Otitis Media
- Syphilis
Also known as: Acute Otitis Media Due To Diplococcus Pneumoniae, Acute Otitis Media Due To Fraenkel's Pneumococcus, Acute Otitis Media Due To Pneumococcus, Acute Otitis Media Due To Pneumonococcus, Acute Otitis Media Due To Streptococcus Pneumoniae, Acute Otitis Media Due To Streptococcus Species, Acute Sinusitis Due To Diplococcus Pneumoniae, Acute Sinusitis Due To Fraenkel's Pneumococcus, Acute Sinusitis Due To Fraenkel's Pneumonococcus, Acute Sinusitis Due To Group A Beta-Hemolytic Strep, Acute Sinusitis Due To Pneumococcus, Acute Sinusitis Due To Streptococcus Epidemicus, Acute Sinusitis Due To Streptococcus Pneumoniae, Acute Sinusitis Due To Streptococcus Pyogenes, Acute Sinusitis From Fraenkel-Weichselbaum Pneumococcus, Bacterial Otitis Media, Cervicitis Due To Chlamydia Trachomatis, Diphtheria Carrier, Diphtheritis, Diphtheritis Prophylaxis, Post-Exposure, Eaton Agent Pneumonia, Epidemic Sore Throat, Fraenkel-Weichselbaum Pneumococcus Acute Otitis Media, Infection Due To Listeria Monocytogenes, Infection Of Skin And/Or Subcutaneous Tissue, Infection Of The Lungs Due To Chlamydia, Legionellosis, Ngu Due To Chlamydia Trachomatis, Nongonococcal Urethritis Due To Chlamydia Trachomatis, Pharyngitis Due To Group A Beta-Hemolytic Streptococci, Pharyngitis Due To Streptococcus Epidemicus, Pharyngitis Due To Streptococcus Pneumoniae, Pneumonia Due To Streptococcus Pneumoniae, Post-Exposure Diphtheria Prophylaxis, Primary Atypical Pneumonia, Rectal Infection Due To Chlamydia Trachomatis, Rheumatic Fever Prophylaxis, Septic Sore Throat, Skin & Skin Soft Tissue Streptococcus Pyogenes Infection, Skin And Skin Soft Tissue Staphylococcus Aureus Infection, Skin And Soft Tissue Skin Infection, Streptococcal Pharyngitis, Syriac Ulcer, Syriac Ulcer Prophylaxis, Post-Exposure, Trachelitis Due To Chlamydia Trachomatis, Urethritis Due To Chlamydia Trachomatis.
Dosing
Dosage of erythromycin ethylsuccinate is expressed in terms of erythromycin. Since the ethylsuccinate has different absorption characteristics in adults than do other commercially available forms of erythromycin, higher oral doses are needed to achieve therapeutic effects. The manufacturer states that, for adults, 400 mg of erythromycin as the ethylsuccinate provides erythromycin activity similar to that provided by 250 mg of erythromycin as the base, stearate, or estolate.
The usual adult oral dosage of erythromycin as the ethylsuccinate is 400 mg every 6 hours. In severe infections, dosage may be increased up to 4 g daily. The usual oral dosage of erythromycin as the ethylsuccinate in children is 30-50 mg/kg daily in 4 equally divided doses every 6 hours. For more severe infections, this dosage may be doubled. An alternative pediatric dosage of 0.9-3 g/m2 daily in 4 equally divided doses has been recommended. The manufacturer states that adults and children may receive one-half the total daily dose of erythromycin ethylsuccinate every 12 hours as an alternative dosage schedule, but some clinicians believe this schedule is inadequate for all but minor infections caused by highly susceptible organisms. The manufacturer also states that adults and children may receive one-third the total daily dose every 8 hours as an alternative dosage schedule.
Erythromycin ethylsuccinate is administered orally. Erythromycin ethylsuccinate oral suspensions, chewable tablets, and film-coated tablets may be administered without regard to meals. Chewable tablets should not be swallowed whole.
The fixed-combination preparation containing erythromycin ethylsuccinate and sulfisoxazole acetyl is administered orally and may be given without regard to meals. Because the fixed-combination preparation contains a sulfonamide, the preparation should not be used in infants younger than 2 months of age, pregnant women at term, or mothers who are nursing infants younger than 2 months of age.
No dosing information is available for this tab.
No dosing information is available for this tab.
Drug interactions
There is no enhanced messaging for this drug.
There are no contraindication interactions for this drug.
There are no severe interactions for this drug.
There are no moderate interactions for this drug.
Contraindications
There is no enhanced messaging for this drug.
There are no contraindication contraindications for this drug.
There are no severe contraindications for this drug.
There are no moderate contraindications for this drug.
Adverse reactions
There is no enhanced messaging for this drug.
There are no severe adverse reactions for this drug.
There are no less severe adverse reactions for this drug.
Precautions
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
ICD codes
No ICD codes are available for this drug.
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.